Asset profile
lifileucel · Amtagvi
Cell therapy
Evidence outlook
Approved: Melanoma
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Competitive landscape
4 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 4 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Lifileucel (Amtagvi): this drug | Approved | Cell therapy | — | ||
| Intismeran Autogene | Phase 3 | Vaccine | Patient-specific tumor neoantigens (personalized, up to 34 per patient) | ||
| Naporafenib | Phase 3 | Small molecule | Pan-RAF | ||
| EIK1001 | Phase 2/3 | Small molecule | Toll-like receptor 7 and 8 (TLR7/8) | ||
| RP1 | Phase 2 | Biologic (subtype unspecified) | No discrete molecular target |
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(8 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (3)
May 2027 (1)
November 2027 (1)
What to watch
December 2027 (1)
What to watch
2028 (3)
March 2028 (1)
May 2028 (1)
What to watch
October 2028 (1)
What to watch
2032 (1)
June 2032 (1)
2033 (1)
September 2033 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.